A randomized, placebo-controlled, double blind, phase 1 trial of the safety, immunogenicity, and tolerability of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults

Trial Profile

A randomized, placebo-controlled, double blind, phase 1 trial of the safety, immunogenicity, and tolerability of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2007

At a glance

  • Drugs PF 5212366 (Primary)
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Wyeth
  • Most Recent Events

    • 04 Dec 2007 Status changed from in progress to completed.
    • 02 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top